MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$110,311K
Free Cash flow
-$75,864K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from offering, net-Unde...
Maturities of investments
Accounts payable
Others
Negative Cash Flow Breakdown
Purchases of investments
Other assets
Rezpegaldesleukin
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
10,131
10,861
21,807
33,425
Cost of goods sold
-
-
0
-
Rezpegaldesleukin
22,389
20,736
13,643
37,888
NKTRTwo Five Five
-
-
1,452
5,034
NKTRZero One Six Five
-
-
638
8,931
TNFR2Program
735
798
-
-
Discovery Research And Other Programs
436
-104
815
1,018
Clinical development, contract manufacturing and other third party costs
23,560
21,430
16,548
52,871
Employee costs
14,962
13,678
12,221
33,782
Facilities costs
2,790
2,833
2,928
9,378
Other operating costs
7,095
7,702
6,846
37,881
Other segment expenses
4,065
4,272
10,929
11,950
Gain on sale of the huntsville manufacturing facility
-
-
0
-
Total operating costs and expenses
52,472
49,915
49,472
145,862
Loss from operations
-42,341
-39,054
-27,665
-112,437
Non-cash interest expense on liabilities related to the sales of future royalties
7,206
7,942
9,769
6,047
Interest income
9,346
4,242
2,776
7,662
Other income (expense), net
-100
-336
-44
405
Total non-operating income (expense), net
2,040
-4,036
-7,037
-8,348
Loss before provision for income taxes and equity method investment
-40,301
-43,090
-34,702
-120,785
Provision (benefit) for income taxes
2
64
31
-169
Loss before equity method investment
-40,303
-43,154
-34,733
-120,616
Loss from equity method investment
-319
-1,750
-1,346
-534
Net loss
-40,622
-44,904
-36,079
-35,522
Non-cash royalty revenue related to the sales of future royalties
10,131
10,861
21,807
11,490
Non-cash interest expense on liabilities related to the sales of future royalties
7,206
7,942
9,769
6,047
Loss from equity method investment
-319
-1,750
-1,346
-534
Stock-based compensation
3,365
3,355
2,193
3,072
Depreciation and amortization expense
156
151
190
196
Impairment of right-of-use assets and property, plant and equipment
-
-
4,441
0
Gain on sale of the huntsville manufacturing facility
-
-
0
-
Provision for net realizable value of inventory
-
-
0
0
Amortization of premiums (discounts), net
-3,570
-1,663
-1,888
-1,433
Accounts receivable
-
-
0
0
Inventory
-
-
0
0
Operating leases, net
4,426
2,409
5,750
3,827
Other assets
40,833
-949
9,858
618
Accounts payable
15,055
-934
-4,793
1,282
Accrued expenses
-2,289
2,326
-2,723
-7,002
Net cash used in operating activities
-75,770
-44,298
-64,959
-48,761
Purchases of investments
535,454
452,253
91,602
149,558
Maturities of investments
136,438
101,482
91,992
54,799
Proceeds (payments) relating to the sale of the huntsville manufacturing facility, net
-
-
-697
-
Proceeds from issuance of tcg pre-funded warrant
-
-
0
0
Purchases of property and equipment
94
18
18
114
Proceeds from sale of future royalties
-
-
0
0
Payment of transaction costs and working capital adjustment from the sale of the huntsville manufacturing facility
0
-697
-
0
Repurchase of common stock from bristol-myers squibb
-
-
0
0
Net cash provided by (used in) investing activities
-399,110
-350,789
372
-94,873
Proceeds from shares issued under equity compensation plans
878
4,055
410
238
Proceeds from offering, net-Two Thousand Twenty Five Secondary Public Offering
-
-
0
108,100
Proceeds from offering, net-Underwritten Offering
351,325
432,400
-
-
Proceeds from offering, net-At The Market Offerings
-
-
72,750
-
Proceeds from offering, net-At The Market Offering
13,580
58,630
-
34,489
Payments of offering costs associated with issuance of common stock and pre-funded warrants
1,214
25
0
1,150
Net cash provided by financing activities
364,569
529,549
38,671
141,677
Effect of foreign exchange rates on cash and cash equivalents
0
0
0
1
Net increase (decrease) in cash and cash equivalents
-110,311
134,462
-25,916
-1,956
Cash and cash equivalents at beginning of period
149,578
15,116
41,032
44,252
Cash and cash equivalents at end of period
39,267
149,578
15,116
41,032
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from offering,
net-Underwritten Offering
$351,325K
Proceeds from offering,
net-At The Market...
$13,580K
Proceeds from shares
issued under equity...
$878K
(302.75%↑ Y/Y)
Net cash provided by
financing activities
$364,569K
(167133.49%↑ Y/Y)
Canceled cashflow
$1,214K
Net increase
(decrease) in cash and cash...
-$110,311K
(-8627.14%↓ Y/Y)
Canceled cashflow
$364,569K
Maturities of investments
$136,438K
(-1.05%↓ Y/Y)
Accounts payable
$15,055K
(421.66%↑ Y/Y)
Non-cash interest
expense on liabilities...
$7,206K
(-30.50%↓ Y/Y)
Stock-based compensation
$3,365K
(-54.43%↓ Y/Y)
Loss from equity
method investment
-$319K
(95.34%↑ Y/Y)
Depreciation and
amortization expense
$156K
(-75.63%↓ Y/Y)
Payments of offering
costs associated with...
$1,214K
Net cash provided by
(used in) investing...
-$399,110K
(-527.75%↓ Y/Y)
Canceled cashflow
$136,438K
Net cash used in
operating activities
-$75,770K
(20.07%↑ Y/Y)
Canceled cashflow
$26,101K
Purchases of investments
$535,454K
(1121.05%↑ Y/Y)
Purchases of property and
equipment
$94K
(141.03%↑ Y/Y)
Other assets
$40,833K
(721.09%↑ Y/Y)
Net loss
-$40,622K
(56.07%↑ Y/Y)
Non-cash royalty revenue
related to the sales of...
$10,131K
(-53.17%↓ Y/Y)
Operating leases, net
$4,426K
(-20.68%↓ Y/Y)
Amortization of premiums
(discounts), net
-$3,570K
(-62.79%↓ Y/Y)
Accrued expenses
-$2,289K
(-158.10%↓ Y/Y)
Interest income
$9,346K
Loss before equity
method investment
-$40,303K
Loss from equity
method investment
-$319K
(95.34%↑ Y/Y)
Total non-operating
income (expense), net
$2,040K
Canceled cashflow
$7,306K
Loss before
provision for income taxes...
-$40,301K
Provision (benefit) for
income taxes
$2K
Canceled cashflow
$2,040K
Revenue
$10,131K
Non-cash interest
expense on liabilities...
$7,206K
(-30.50%↓ Y/Y)
Other income
(expense), net
-$100K
Loss from operations
-$42,341K
Canceled cashflow
$10,131K
Total operating costs
and expenses
$52,472K
Clinical development,
contract manufacturing...
$23,560K
Employee costs
$14,962K
Other operating costs
$7,095K
Other segment
expenses
$4,065K
Facilities costs
$2,790K
Rezpegaldesleukin
$22,389K
TNFR2Program
$735K
Discovery Research And
Other Programs
$436K
Buy us a coffee
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)